NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced yesterday that it has signed a master companion diagnostics development agreement with Merck KGaA, which will initially focus on a test for use with the German drugmaker's investigational Bruton's tyrosine kinase (BTK) inhibitor M7583.

BTK is an enzyme associated with B cell development and implicated in certain autoimmune diseases and cancers. Merck is developing M7583 as a treatment for B cell lymphoma and expects to begin clinical testing of the drug this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.